3 Branded Generics Maker, Pumps and Valves Maker and Chromium and Barium Chemicals Maker Stocks With a Strong Future Roadmap: Lincoln Pharmaceuticals, Kirloskar Brothers and Vishnu Chemicals
- November 4, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Lincoln Pharmaceuticals, Kirloskar Brothers and Vishnu Chemicals: ROE of 11.6% to 15.2% and FY22 to FY26 revenue CAGR of 9.9% to 10.9%. Prices as of 3 Nov 2026.
Quick Answer
The three branded drug, pump and chromium chemical stocks to watch are Lincoln Pharmaceuticals, Kirloskar Brothers and Vishnu Chemicals. Their return on equity ranges from 11.6% to 15.2%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.9% to 10.9%. Kirloskar Brothers has the highest return on equity at 15.2%, while Vishnu Chemicals has the fastest revenue growth at 10.9% a year. Prices are based on the 3 November 2026 close, and this article is educational, not investment advice.
Branded drug, pump and chromium chemical stocks offer a focused view of a sector where demand keeps widening. Lincoln Pharmaceuticals, Kirloskar Brothers and Vishnu Chemicals cover a branded generics maker, a pumps and valves maker and a specialty chemicals maker.
This list covers three branded drug, pump and chromium chemical stocks with complete current figures: Lincoln Pharmaceuticals, Kirloskar Brothers and Vishnu Chemicals. Every figure comes from the latest reported financials and the 3 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Branded Drug, Pump and Chromium Chemical Stocks?
Branded drug, pump and chromium chemical stocks are listed companies that make branded generics for India and emerging markets, produce pumps, valves and hydro systems for water and power projects, and manufacture chromium and barium compounds for leather, pigments and cement. Their earnings depend on prescriptions, water projects and industrial chemical demand.
Branded Drug, Pump and Chromium Chemical Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Lincoln Pharmaceuticals | 504.35 | 1,067 | 11.1 | 36.0 | 11.6 | 0.01 |
| Kirloskar Brothers | 1,743.4 | 13,186 | 35.0 | 43.0 | 15.2 | 0.10 |
| Vishnu Chemicals | 519.05 | 3,788 | 25.3 | 33.2 | 13.3 | 0.49 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing branded drug, pump and chromium chemical stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in branded drug, pump and chromium chemical stocks can use the coming numbers to test whether growth is holding.
Why Do Branded Drug, Pump and Chromium Chemical Stocks Have a Strong Roadmap in India?
Branded drug, pump and chromium chemical stocks have a strong roadmap in India because growing medicine use, expanding water and irrigation projects and steady industrial demand keep widening the market for these companies.
- Branded generics. Emerging markets buy trusted medicines.
- Pumps and valves. Water and power projects need flow equipment.
- Specialty chemicals. Leather and pigment makers need compounds.
Why Lincoln Pharmaceuticals Features Among These Branded Drug, Pump and Chromium Chemical Stocks
Among the branded drug, pump and chromium chemical stocks on this list, Lincoln Pharmaceuticals is an Ahmedabad-based maker of branded generics and formulations in India and exports to emerging markets, with products across anti-infectives, respiratory and pain care.
Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%.
In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P/E of 11.1, below the industry P/E of 36.0.
Roadmap: The company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.
What to watch: Track branded product growth, export orders and new launches.
Why Kirloskar Brothers Features Among These Branded Drug, Pump and Chromium Chemical Stocks
Among the drug maker and pump shares on this list, Kirloskar Brothers is a Pune-based maker of pumps, valves and hydro systems used in irrigation, water supply, power plants, buildings and industry. It has served customers for over a century.
In the June 2026 quarter, revenue grew 12.5% year on year to Rs 1,120 crore. Revenue rose from Rs 3,090 crore in FY22 to Rs 4,615 crore in FY26, a compound annual growth rate of 10.5%.
Net profit grew from Rs 81.5 crore in FY22 to Rs 361 crore in FY26, which works out to a compound annual growth rate of 45.1%. The company has a return on equity of 15.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 13,186 crore. The stock trades at a P/E of 35.0, below the industry P/E of 43.0.
Roadmap: The company benefits from public spending on water supply, irrigation and urban infrastructure, and it is growing its project and aftermarket business. A deep service network supports repeat orders.
What to watch: Follow order inflows from water and irrigation projects and the share of aftermarket sales.
Why Vishnu Chemicals Features Among These Branded Drug, Pump and Chromium Chemical Stocks
Among the three companies on this list, Vishnu Chemicals is a Hyderabad-based specialty chemicals maker that produces chromium and barium compounds used in leather, pigments, cement and industrial applications for customers in India and abroad.
The company has a return on equity of 13.3%, a debt to equity ratio of 0.49 and a market capitalisation of Rs 3,788 crore. The stock trades at a P/E of 25.3, below the industry P/E of 33.2.
Revenue rose from Rs 1,075 crore in FY22 to Rs 1,626 crore in FY26, a compound annual growth rate of 10.9%. Net profit grew from Rs 81.4 crore in FY22 to Rs 142 crore in FY26, which works out to a compound annual growth rate of 15.0%. In the June 2026 quarter, revenue grew 26.9% year on year to Rs 446 crore, while net profit rose 23.0% to Rs 39.6 crore.
Roadmap: The company is expanding capacity for chromium chemicals and moving into higher-value products, which supports export demand. Its position in a niche segment with few producers helps it hold pricing.
What to watch: Track export demand, capacity additions and raw material costs.
Lincoln Pharmaceuticals vs Kirloskar Brothers vs Vishnu Chemicals on Key Financials
The table below sets the three branded drug, pump and chromium chemical stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Lincoln Pharmaceuticals | 482 | 704 | 9.9% | 87.9 | 12.5% |
| Kirloskar Brothers | 3,090 | 4,615 | 10.5% | 361 | 7.8% |
| Vishnu Chemicals | 1,075 | 1,626 | 10.9% | 142 | 8.8% |
Kirloskar Brothers posts the highest return on equity in this group at 15.2%. Kirloskar Brothers has the largest FY26 revenue at Rs 4,615 crore, and Vishnu Chemicals shows the fastest revenue growth with a 10.9% compound annual rate. A useful habit with branded drug, pump and chromium chemical stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Lincoln Pharmaceuticals | 169 | 202 | 19.0% |
| Kirloskar Brothers | 995 | 1,120 | 12.5% |
| Vishnu Chemicals | 352 | 446 | 26.9% |
Key Risks to Check Before Investing in Branded Drug, Pump and Chromium Chemical Stocks
Every theme carries risks that deserve a check before any decision. For these branded drug, pump and chromium chemical stocks, the main points are: Long-term drug maker and pump shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Raw material and energy costs. Input prices can move margins in chemicals.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter branded drug, pump and chromium chemical stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Branded Drug, Pump and Chromium Chemical Stocks
Branded drug, pump and chromium chemical stocks reward patient research into demand, execution and financial strength. Lincoln Pharmaceuticals, Kirloskar Brothers and Vishnu Chemicals each have a clear plan to grow. Based on the 3 November 2026 close, Lincoln Pharmaceuticals trades at Rs 504.35, Kirloskar Brothers at Rs 1,743.4 and Vishnu Chemicals at Rs 519.05. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these branded drug, pump and chromium chemical stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track branded drug, pump and chromium chemical stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are branded drug, pump and chromium chemical stocks?
Ans. Branded drug, pump and chromium chemical stocks are listed companies that make branded generics for India and emerging markets, produce pumps, valves and hydro systems for water and power projects, and manufacture chromium and barium compounds for leather, pigments and cement. Their earnings depend on prescriptions, water projects and industrial chemical demand. This list looks at three of them, Lincoln Pharmaceuticals, Kirloskar Brothers and Vishnu Chemicals, using reported FY22 to FY26 financials and the 3 November 2026 closing prices.
Which branded drug, pump and chromium chemical stocks are covered in this list?
Ans. This list covers Lincoln Pharmaceuticals, Kirloskar Brothers and Vishnu Chemicals. Based on the 3 November 2026 close, Lincoln Pharmaceuticals traded at Rs 504.35, Kirloskar Brothers at Rs 1,743.4 and Vishnu Chemicals at Rs 519.05. Their return on equity ranges from 11.6% to 15.2%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.9% to 10.9%.
Why do branded drug, pump and chromium chemical stocks have a strong future roadmap in India?
Ans. Branded drug, pump and chromium chemical stocks have a strong roadmap in India because growing medicine use, expanding water and irrigation projects and steady industrial demand keep widening the market for these companies. The main drivers are as follows. Branded generics. Emerging markets buy trusted medicines. Pumps and valves. Water and power projects need flow equipment. Specialty chemicals. Leather and pigment makers need compounds. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Lincoln Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%. In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P/E of 11.1, below the industry P/E of 36.0. Looking ahead, the company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.
How has Kirloskar Brothers performed financially?
Ans. Revenue rose from Rs 3,090 crore in FY22 to Rs 4,615 crore in FY26, a compound annual growth rate of 10.5%. Net profit grew from Rs 81.5 crore in FY22 to Rs 361 crore in FY26, which works out to a compound annual growth rate of 45.1%. In the June 2026 quarter, revenue grew 12.5% year on year to Rs 1,120 crore. The company has a return on equity of 15.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 13,186 crore. The stock trades at a P/E of 35.0, below the industry P/E of 43.0. Looking ahead, the company benefits from public spending on water supply, irrigation and urban infrastructure, and it is growing its project and aftermarket business. A deep service network supports repeat orders.
How has Vishnu Chemicals performed financially?
Ans. Revenue rose from Rs 1,075 crore in FY22 to Rs 1,626 crore in FY26, a compound annual growth rate of 10.9%. Net profit grew from Rs 81.4 crore in FY22 to Rs 142 crore in FY26, which works out to a compound annual growth rate of 15.0%. In the June 2026 quarter, revenue grew 26.9% year on year to Rs 446 crore, while net profit rose 23.0% to Rs 39.6 crore. The company has a return on equity of 13.3%, a debt to equity ratio of 0.49 and a market capitalisation of Rs 3,788 crore. The stock trades at a P/E of 25.3, below the industry P/E of 33.2. Looking ahead, the company is expanding capacity for chromium chemicals and moving into higher-value products, which supports export demand. Its position in a niche segment with few producers helps it hold pricing.
What risks should investors check before buying branded drug, pump and chromium chemical stocks?
Ans. Investors should check a few risks before buying branded drug, pump and chromium chemical stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Raw material and energy costs. Input prices can move margins in chemicals. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of branded drug, pump and chromium chemical stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 3 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
